- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01526590
Contrast Enhanced Endoscopic Ultrasound for Vascular Involvement in Pancreatic Lesions
A Pilot Study of the Effects of Contrast Enhanced Endoscopic Ultrasound on Determining Vascular Involvement in Pancreatic Lesions
In the US, pancreas cancer is the fifth leading cause of cancer related deaths. It was estimated to have taken 36,800 lives in 2010. Unfortunately, curing pancreatic cancer requires surgical removal. Surgical removal of the pancreas is associated with high morbidity and mortality, as well as high rates of complications. One way to aid surgeons in removing pancreatic tumors is by providing them with a good idea of where the tumor is located and what surrounding structures are involved. This currently happens through many different modalities of imaging; usually computed tomography (CT) and endoscopic ultrasound. Even with these forms of imaging (and sometimes others), surgeons will occasionally open a patient and find that the tumor cannot be removed due to its involvement with surrounding structures.
One way to avoid potentially unnecessary procedures or to help a surgeon navigate this delicate procedure would be to provide more detailed information about the tumor. Several of the techniques currently used to image the body have rapidly advanced over recent years. Typical advancements come through better resolution of the images or contrast to enhance desired parts of the images. Ultrasound has not seen such a two pronged advance. Ultrasound has seen substantial advances in resolution to enhance picture quality, but contrast has not been used clinically to assess pancreatic masses whereas it is for cardiologists to use contrast to look at potential defects in the heart.
The contrast that is used with ultrasound is different from that of CT scans. CT scanners use a dye that can be potentially hazardous. This dye can lead to serious kidney damage in some patients. Ultrasound contrast, on the other hand, is made of small micro bubbles filled with a harmless gas. Because of the way ultrasound works, these micro bubbles reflect the sound waves differently than the surrounding tissue and thus provide contrast between normal tissue and abnormal tissue. The contrast used in this study, Definity, and is the same contrast used by Cardiologists.
The CE-EUS will be used for research purposes only and will not be used for any clinical decision making. The surgeon will be blinded to the results of the research CE-EUS. The investigators will compare the research pre-operative contrast enhanced endoscopic ultrasounds images with already completed standard-of-care CT scans, the actual pancreatic involvement seen in surgery and the pathology reports.
Study Overview
Detailed Description
CT Scan of the abdomen - Standard Therapy
a. The standard of care is that patients in question of pancreatic lesions undergo CT scanning. After a CT scan, if it appears that the pancreatic mass may be resectable, the standard protocol is to look at the pancreas while the patient is sedated with endoscopic ultrasound for diagnostic tissue sampling and further staging. For this reason, the endoscopist will not be blinded to the CT scan because it is the standard of care that they interpret the results of the EUS with that information.
Consent for Endoscopic Ultrasound (EUS) - Standard Therapy
a. Before being sedated and having endoscopic ultrasound, all patients are informed about the risks of the procedure, alternatives, and what will be done. The patients who decide to undergo endoscopic ultrasound will sign a consent form. Our goal is to enroll 30 patients (This number is limited by both the amount of contrast received from Lantheus and the number of patients typically seen in a year. Ideally we will enroll as many as possible for the purposes of power).
Consent for Contrast Enhanced Endoscopic Ultrasound (CE-EUS) -- Performed exclusively for research purposes
- After the patient has been informed about the standard of care and signed a consent form, the patient will be asked if they wish to participate in an experimental study. If the patient is interested, they will be questioned about potential structural heart defects, congenital heart defects, recent worsening of heart or lung conditions, pulmonary hypertension, potential pregnancy, attempts to become pregnant, if they are nursing, or allergies to the contrast. If they report any of these relative contraindications, we will exclude them from participating in the study.
- If they are free of all of those relative contraindications, they will be provided information about the study (see included forms) and will be asked to sign a consent form as well as a HIPAA authorization.
EUS - Standard of Care
- At this point they will undergo an endoscopic ultrasound of the pancreas as per standard protocol. They will have a peripheral IV started by the endoscopic technician or nurse anesthetist. While the patient is being prepared, both research questionnaires (EUS and CE-EUS) will be filled out ahead of time with the exception of the findings, in order to reduce the time to complete the survey. The patient will be sedated in one of two ways. Either they will be consciously sedated with meperidine and midazolam under the surveillance of the attending gastroenterologist or they will have propofol based sedation under the surveillance of an anesthesiologist as per standard endoscopic ultrasound protocol.
- The patient will undergo their endoscopic ultrasound and video and images will be recorded.
EUS Questionnaire - Preformed exclusively for research purposes. Duration less than one minute.
- The endoscopist will then fill out a survey (see attached) to record their impressions of the tumor and the extent of its invasion into the vasculature. This should not take more than one minute. EUS criteria for vascular invasion will be loss of normal hyperechoic interface between the tumor and the vessel, irregular tumor and vessel interface, tumor within vessel lumen, vessel encasement, or collaterals with venous occlusion.
- Decision about FNA - Standard of care, but important that it is done before CU-EUS a. If the endoscopist feels that FNA is warranted they will make the decision at this time.
CE-EUS - Experimental Procedure performed exclusively for research purposes
a. Dosing of Contrast - procedure performed exclusively for research purposes i. While the patient is still sedated and before tissue sampling, the experimental aspect of the procedure will begin. At this time, they will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc. A saline flush will follow the injection of the contrast and a timer will be started. The remaining contrast will be properly disposed of in a sharps container.
b. Recording of CE-EUS images - procedure performed exclusively for research purposes. Duration 3-4 minutes i. The endoscopist will perform an additional reading with the contrast and record a 3-4 minute segment for review later using the harmonic mode of the ultrasound probe at a mechanical index of 0.3. The mechanical index may need to be be optimized, however a previous study found 0.3 to be optimal. Aspects that will be analyzed later are sequence of filling (central vs peripheral), timing (arterial [0-30s], venous [60-180s], post-venous/equilibrium phase [>180s]), pattern of perfusion (homogenous vs heterogenous, and with or without defect) and degree of venous washout. After the experimental portion of the procedure the endoscopist will fill out a form (see attached) to record their impressions of the characteristics of the tumor with contrast. The images will be saved for further comparison with the CT scan and the pathology results at a later time.
FNA - Standard of care (if previously decided upon)
a. If it was determined after the normal EUS but before the CE-EUS that the patient needed tissue sampling, the patient will then undergo the sampling in the standard fashion. If the patient was not to receive tissue sampling, the exam would be over. When the exam is finished the endoscopist will fill out the remaining questionnaire while the patient recovers.
- Patient recovery in Endoscopy Suite - Standard of Care
Patient transport to recovery room - Standard of Care
- After the patient recovers in the endoscopy room, the patient will be transported to the recovery room where they will be monitored for at least 30 minutes. The patient will be informed of the findings of their EUS per standard care. The patient will not be informed of the findings of CE-EUS as the significance is unknown.
- If an incidental lesion is found on EUS then the patient will undergo the appropriate follow-up for that lesion as per standard protocol. If an incidental finding is not apparent on EUS or CT, but happens to show up with the CU-EUS, the patient will be informed of the finding and its unknown significance.
Radiologist's Interpretation - Research purposes only
a. After CE-EUS and EUS, the images will be randomly ordered and interpreted by a radiologist. An excel sheet will be made and the studies will be placed into three separate blocks in chronological order Participant 1-10, 11-20, and 21-30. In a separate column a random number generator will order the first block of 1-10's EUS into a random order for and then again a different random order for CE-EUS. The radiologist will fill out the attached questionnaire. The Surgeon will be blinded to these readings as they are for research purposes only and not the standard of care.
Surgery - Standard of Care with questionnaire after the procedure for research purposes
a. The surgeon will record their impressions of the vascular involvement of the tumor on the attached questionnaire after the surgery.
- Pathology review - Standard of care a. If the patient has pathology sent from surgery, the surgeon will label the vessels encompassed and the pathologist will report whether there was invasion into the vasculature. We will retrospectively review the pathology results of the surgery for comparison.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- Fletcher Allen Healthcare
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with pancreatic lesion undergoing EUS for diagnosis and pre-operative assessment.
Exclusion Criteria:
- Pregnant women, breastfeeding women and individuals with metastatic lesions on CT.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Definity
Patients enrolled in the study will undergo contrast enhanced endoscopic ultrasound of the pancreas with Definity contrast after they have undergone their standard of care endoscopic ultrasound of the pancreas.
|
While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated.
The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Lesion Margin
Time Frame: Up to six months
|
Up to six months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Sequence of filling
Time Frame: Up to six months
|
Up to six months
|
Pattern of Perfusion
Time Frame: Up to six months
|
Up to six months
|
Degree of venous washout
Time Frame: Up to six months
|
Up to six months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: James Hebert, M.D., University of Vermont/Fletcher Allen Healthcare
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHRMS_M11-203
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Tumors
-
Hellenic Cooperative Oncology GroupNovartisTerminatedGastrointestinal Tumors | Pancreatic Neuroendocrine Tumors | Pancreatic Tumors | Gastrointestinal Neuroendocrine TumorsGreece
-
Memorial Sloan Kettering Cancer CenterRecruitingNeuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine TumorsUnited States
-
Oslo University HospitalUniversity Hospital of North Norway; Haukeland University Hospital; St. Olavs...RecruitingPancreatic Neuroendocrine Tumors, WHO Grade I-IINorway
-
Wakayama Medical UniversityOsaka University; Kyoto Prefectural University of Medicine; Nara Medical University and other collaboratorsCompletedPancreatic Cancer | Chronic Pancreatitis | Pancreatic Cystic Lesions | Pancreatic Neuroendocrine Tumors | Pancreatic PseudocystsJapan
-
Qilu Hospital of Shandong UniversityLanZhou University; First Affiliated Hospital, Sun Yat-Sen University; Wuhan... and other collaboratorsRecruitingPancreatic Neoplasms | Pancreatic Diseases | Pancreatitis | Pancreatic Ductal Adenocarcinoma | Pancreatic Neuroendocrine Tumor | Pancreatic Elastase 1China
-
HaEmek Medical Center, IsraelUnknownPancreatic Cancer | Pancreatic Cyst | Pancreatic Neuroendocrine Tumor | Pancreatic Cancer Stage
-
Singapore General HospitalUnknownPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Neuroendocrine TumorSingapore
-
Fudan UniversityTongji Hospital; Qilu Hospital of Shandong University; Tianjin Medical University... and other collaboratorsNot yet recruitingPancreatic Neuroendocrine Tumor | Solid Pseudopapillary Tumor of the Pancreas | Pancreatic Tumor, Benign
-
Vanquish Oncology, Inc.University of Illinois at ChicagoCompletedSolid Tumor | Neuroendocrine Tumors | Pancreatic Neuroendocrine TumorUnited States
-
Francesco De CobelliCompleted
Clinical Trials on Definity Contrast
-
Rabih A. ChaerNational Institute on Aging (NIA)CompletedAbdominal Aortic AneurysmUnited States
-
University of Alabama at BirminghamWithdrawnThyroid NodulesUnited States
-
Dr. Amer JohriLantheus Medical ImagingCompletedMyocardial Infarction | Vascular Diseases | Atherosclerosis | Acute Coronary Syndrome | Cardiac Disease | AtheromaCanada
-
UNC Lineberger Comprehensive Cancer CenterCompletedKidney CancerUnited States
-
Medical University of South CarolinaSouth Carolina Spinal Cord Injury Research FundRecruitingSpinal Cord Diseases | Spinal Stenosis | Spinal Cord Injuries | Spine Degeneration | Spinal Cord Compression | Spine Disease | Spinal InjuryUnited States
-
Dr. Amer JohriLantheus Medical ImagingRecruitingMyocardial Infarction | Cardiovascular Diseases | Atherosclerosis | Carotid Artery Diseases | Acute Coronary Syndrome | Ischemic Heart DiseaseCanada
-
University of MichiganRecruitingKidney; Obstruction | Renal ObstructionUnited States
-
University of North Carolina, Chapel HillLantheus Medical ImagingCompletedChronic Kidney Diseases | Cystic Kidney DiseaseUnited States
-
M.D. Anderson Cancer CenterCompleted
-
Thomas Jefferson UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsRecruitingLiver Diseases | Portal HypertensionUnited States, Switzerland